CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma

Immunotherapy with CD19-targeting bispecific T-cell engagers (CD19BiTEs) has demonstrated highly effective killing of cancer cells in patients with precursor acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. However, there are some drawbacks to this therapy, such as toxicity, short half-life...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Wen, Ye, Qian, Hao, Yuanyuan, Chen, Jie, Huang, Yu, Yang, Liu, Wang, Shibing, Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885649/
https://www.ncbi.nlm.nih.gov/pubmed/35228544
http://dx.doi.org/10.1038/s41408-022-00634-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885649/
https://www.ncbi.nlm.nih.gov/pubmed/35228544
http://dx.doi.org/10.1038/s41408-022-00634-4

Ejemplares similares